MCID: BRS113
MIFTS: 55

Breast Lobular Carcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Breast Lobular Carcinoma

MalaCards integrated aliases for Breast Lobular Carcinoma:

Name: Breast Lobular Carcinoma 11 28 5 14
Lobular Breast Carcinoma 16
Cancer, Breast, Lobular 38

Classifications:



External Ids:

Disease Ontology 11 DOID:0050938

Summaries for Breast Lobular Carcinoma

Disease Ontology: 11 A breast carcinoma that derives from breast lobules (milk glands).

MalaCards based summary: Breast Lobular Carcinoma, also known as lobular breast carcinoma, is related to cervical adenocarcinoma and linitis plastica. An important gene associated with Breast Lobular Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Oxybutynin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone marrow, and related phenotypes are Decreased viability in pancreas lineage and Increased cell death in HCT116 cells

Related Diseases for Breast Lobular Carcinoma

Diseases related to Breast Lobular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 577)
# Related Disease Score Top Affiliating Genes
1 cervical adenocarcinoma 30.7 TP53 PGR KRT7 ESR1
2 linitis plastica 30.7 PIP PGR KRT7 GATA3 ERBB2 CDH1
3 papillary carcinoma 30.6 MUC1 KRT7 ESR1 ERBB2 CDH1
4 gastric adenocarcinoma 30.5 TP53 PTEN PIK3CA ERBB2 CDH1
5 fasciitis 30.5 TP53 MUC1 ESR1
6 leiomyoma, uterine 30.5 PGR ESR1 CYP19A1
7 inherited cancer-predisposing syndrome 30.4 TP53 PTEN EGFR CDH1 BRCA2 BRCA1
8 bap1 tumor predisposition syndrome 30.4 TP53 PTEN EGFR CDH1 BRCA2 BRCA1
9 gastroesophageal reflux 30.3 TP53 GATA3 EGFR EGF
10 anus cancer 30.3 TP53 PIK3CA KRT7 ERBB2 EGFR
11 leiomyoma 30.3 TP53 PGR ESR1 EGF CYP19A1
12 breast metaplastic carcinoma 30.3 TP53 PGR KRT7 KRT5 ESR1 ERBB2
13 breast disease 30.3 TP53 PGR ESR1 ERBB2 EGF CYP19A1
14 diffuse gastric cancer 30.2 TP53 PTEN PIK3CA ERBB2 CTNND1 CDH1
15 diffuse gastric and lobular breast cancer syndrome 30.2 TP53 PTEN PIK3CA ERBB2 CTNND1 CDH1
16 gastric diffuse adenocarcinoma 30.2 PIP PGR KRT7 GATA3 ESR1 ERBB2
17 endometrial adenocarcinoma 30.2 TP53 PTEN PGR KRT7 ESR1 EGFR
18 skin carcinoma 30.1 TP53 PTEN KRT7 KRT5 ERBB2 EGFR
19 mammary paget's disease 30.1 PIP PGR MUC1 KRT7 ESR1 ERBB2
20 colon adenocarcinoma 30.1 TP53 PIK3CA ESR1 EGFR EGF CTNND1
21 spinal cord disease 30.0 TP53 PTEN EGFR
22 bilateral breast cancer 29.9 TP53 PTEN PGR ESR1 ERBB2 CYP19A1
23 breast fibroadenoma 29.9 TP53 PGR KRT5 ESR1 ERBB2 EGFR
24 sweat gland cancer 29.9 TP53 PIP PGR KRT7 KRT5 GATA3
25 colonic benign neoplasm 29.8 TP53 PTEN PIK3CA KRT7 ESR1 ERBB2
26 squamous cell carcinoma 29.8 TP53 PTEN PIK3CA MUC1 KRT7 ERBB2
27 meningioma, familial 29.7 TP53 PTEN PIK3CA PGR MUC1 ESR1
28 gastric cancer 29.7 TP53 PTEN PIK3CA MUC1 ESR1 ERBB2
29 lobular neoplasia 29.7 TP53 PTEN PIP PIK3CA PGR KRT5
30 adenocarcinoma 29.7 TP53 PTEN PIK3CA MUC1 KRT7 ERBB2
31 apocrine adenocarcinoma 29.6 TP53 PIP PIK3CA PGR KRT7 KRT5
32 leukemia, acute myeloid 29.6 TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
33 bladder cancer 29.6 TP53 PTEN PIK3CA MUC1 KRT7 ESR1
34 renal cell carcinoma, nonpapillary 29.6 TP53 PTEN PIK3CA MUC1 KRT7 ESR1
35 ovarian cancer 29.5 TP53 PTEN PIK3CA PGR MUC1 KRT7
36 breast carcinoma in situ 29.4 TP53 PTEN PIP PIK3CA PGR MUC1
37 lung cancer 29.3 TP53 PTEN PIK3CA MUC1 KRT7 ESR1
38 breast ductal carcinoma 29.1 TP53 PTEN PIP PGR MUC1 KRT7
39 breast cancer 29.1 TP53 PTEN PIP PIK3CA PGR MUC1
40 ductal carcinoma in situ 29.1 TP53 PTEN PIP PIK3CA PGR MUC1
41 colorectal cancer 29.0 TP53 PTEN PIK3CA PGR MUC1 KRT7
42 endometrial cancer 28.9 TP53 PTEN PIK3CA PGR MUC1 KRT7
43 breast adenocarcinoma 28.9 TP53 PTEN PIP PIK3CA PGR MUC1
44 uterine corpus adenosarcoma 10.5 PGR ESR1
45 adult cystic nephroma 10.5 PGR ESR1
46 her2-receptor negative breast cancer 10.5 PGR ERBB2
47 vagina leiomyosarcoma 10.5 PGR ESR1
48 euryblepharon 10.5 CTNND1 CDH1
49 vulvar benign neoplasm 10.5 PGR ESR1
50 mucoepidermoid esophageal carcinoma 10.5 TP53 KRT5

Graphical network of the top 20 diseases related to Breast Lobular Carcinoma:



Diseases related to Breast Lobular Carcinoma

Symptoms & Phenotypes for Breast Lobular Carcinoma

GenomeRNAi Phenotypes related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
2 no effect GR00402-S-2 10.18 AR BRCA1 BRCA2 CTNND1 CYP19A1 EGF
3 Decreased viability in pancreas lineage GR00235-A 9.13 KRT7 PGR TP53
4 Increased cell death in HCT116 cells GR00103-A-0 8.85 PIK3CA

MGI Mouse Phenotypes related to Breast Lobular Carcinoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.45 AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
2 neoplasm MP:0002006 10.44 AR BRCA1 BRCA2 CDH1 CTNND1 EGFR
3 normal MP:0002873 10.44 AR BRCA1 BRCA2 CDH1 CYP19A1 EGF
4 homeostasis/metabolism MP:0005376 10.43 AR BRCA1 BRCA2 CDH1 CYP19A1 EGFR
5 growth/size/body region MP:0005378 10.41 AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
6 digestive/alimentary MP:0005381 10.41 AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
7 nervous system MP:0003631 10.35 AR BRCA1 BRCA2 CTNND1 CYP19A1 EGFR
8 cellular MP:0005384 10.34 AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1
9 muscle MP:0005369 10.3 AR BRCA1 CYP19A1 EGFR ERBB2 ESR1
10 renal/urinary system MP:0005367 10.27 AR BRCA1 CTNND1 CYP19A1 EGFR ESR1
11 immune system MP:0005387 10.27 AR BRCA1 BRCA2 CDH1 CYP19A1 EGF
12 embryo MP:0005380 10.26 AR BRCA1 BRCA2 CDH1 EGFR ERBB2
13 limbs/digits/tail MP:0005371 10.25 AR BRCA1 BRCA2 EGFR ERBB2 ESR1
14 cardiovascular system MP:0005385 10.22 AR BRCA1 CDH1 CYP19A1 EGFR ERBB2
15 reproductive system MP:0005389 10.2 AR BRCA1 BRCA2 CDH1 CYP19A1 EGF
16 no phenotypic analysis MP:0003012 10.19 CDH1 EGFR ESR1 GATA3 MUC1 PGR
17 adipose tissue MP:0005375 10.19 AR BRCA1 CYP19A1 EGFR ESR1 GATA3
18 pigmentation MP:0001186 10.15 AR BRCA1 CYP19A1 EGFR GATA3 PTEN
19 skeleton MP:0005390 10.03 AR BRCA1 BRCA2 CYP19A1 EGFR ERBB2
20 hematopoietic system MP:0005397 9.93 AR BRCA1 BRCA2 CYP19A1 EGFR ERBB2
21 mortality/aging MP:0010768 9.83 AR BRCA1 BRCA2 CDH1 CTNND1 EGFR
22 integument MP:0010771 9.58 AR BRCA1 BRCA2 CDH1 CTNND1 CYP19A1

Drugs & Therapeutics for Breast Lobular Carcinoma

Drugs for Breast Lobular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
2
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
3
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
4
Fulvestrant Approved, Investigational Phase 3 129453-61-8 17756771 104741
5 Neurotransmitter Agents Phase 3
6 Parasympatholytics Phase 3
7 Mandelic Acids Phase 3
8 Anti-Infective Agents Phase 3
9 Muscarinic Antagonists Phase 3
10 Cholinergic Antagonists Phase 3
11 Cholinergic Agents Phase 3
12 Antineoplastic Agents, Hormonal Phase 3
13 Estrogens Phase 3
14 Estrogen Receptor Antagonists Phase 3
15 Estrogen Antagonists Phase 3
16 Hormones Phase 3
17 Hormone Antagonists Phase 3
18 Hypoglycemic Agents Phase 3
19 Aromatase Inhibitors Phase 3
20
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
21
Epirubicin Approved Phase 2 56420-45-2 41867
22
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
23
Vinorelbine Approved, Investigational Phase 2 71486-22-1 44424639 60780
24
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
25
Trastuzumab Approved, Investigational Phase 2 180288-69-1
26
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
27
Entrectinib Approved, Investigational Phase 2 1108743-60-7 25141092
28
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
29
Goserelin Approved Phase 2 65807-02-5 5311128 47725
30
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
31 Antimetabolites Phase 2
32 Antirheumatic Agents Phase 2
33 Anti-Bacterial Agents Phase 2
34 Alkylating Agents Phase 2
35 Antineoplastic Agents, Alkylating Phase 2
36 Antimitotic Agents Phase 2
37 Angiogenesis Inhibitors Phase 2
38 Tubulin Modulators Phase 2
39 Antibiotics, Antitubercular Phase 2
40 Antineoplastic Agents, Immunological Phase 2
41 Immunosuppressive Agents Phase 2
42 Immunologic Factors Phase 2
43 Omega 3 Fatty Acid Phase 2
44 Protein Kinase Inhibitors Phase 2
45 Pharmaceutical Solutions Phase 2
46
Atorvastatin Approved Phase 1 134523-00-5 60823
47
Carbamide peroxide Approved Phase 1 124-43-6
48
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 1 62-33-9, 60-00-4 6049
49
Pentetic acid Approved Phase 1 67-43-6
50
Tamoxifen Approved Phase 1 10540-29-1, 54965-24-1 2733526

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
2 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Active, not recruiting NCT01905046 Phase 3 metformin hydrochloride
3 Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study Active, not recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
4 RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction Active, not recruiting NCT03414970 Phase 3
5 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
6 Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy Unknown status NCT02314156 Phase 2 Telapristone Acetate
7 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Completed NCT01849250 Phase 2 Docosahexaenoic Acid
8 A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma Completed NCT01869764 Phase 2 omega-3 fatty acid
9 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Recruiting NCT03979508 Phase 2 Abemaciclib
10 Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast Recruiting NCT04551495 Phase 2 Entrectinib;Letrozole;Goserelin
11 [18F]Fluoroestradiol-Positron Emission Tomography (PET)/CT Imaging of Invasive Lobular Carcinoma Recruiting NCT04252859 Phase 2 [18F]Fluoroestradiol (FES) PET/CT
12 Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours Recruiting NCT03620643 Phase 2 Crizotinib Oral Capsule [Xalkori];Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
13 Accelerated, Hypofractionated Post-Mastectomy Radiation Therapy in Women With Breast Cancer: A Phase II Trial Active, not recruiting NCT01417286 Phase 2
14 Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer Terminated NCT01754519 Phase 2
15 A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer Withdrawn NCT01100489 Phase 2
16 A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Completed NCT00637481 Phase 1 atorvastatin calcium
17 Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer Completed NCT01077453 Phase 1 letrozole
18 Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging Recruiting NCT04750473 Phase 1 Fluciclovine F18;Gallium Ga 68 Gozetotide
19 Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery Active, not recruiting NCT03317405 Phase 1 Endoxifen Hydrochloride
20 A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer Active, not recruiting NCT03323658 Phase 1 Bexarotene
21 Monitoring Response After The First Chemotherapy Cycle In Newly Diagnosed Breast Cancer As A Guide For Neoadjuvant Therapy Unknown status NCT01038258
22 A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients Completed NCT01819233
23 Diet, Exercise and Estrogen Metabolites Study (DEEM) Completed NCT01874184
24 Living Well After Breast Surgery Completed NCT03834532
25 Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial Completed NCT01975363
26 Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial Completed NCT01688388
27 A Pilot Study of Broccoli Sprout Extract in Patients With Breast Cancer Completed NCT01753908 Early Phase 1 Broccoli Sprout Extract
28 Psychoeducation for Spouses/Partners of Women With Breast Cancer Completed NCT01723943
29 Choosing Neoadjuvant Chemotherapy Versus Hormonal Therapy for Breast Cancer Based on Gene Expression Profile Completed NCT01293032 Systemic Chemotherapy;Tamoxifen Citrate;Aromatase Inhibition Therapy
30 Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer Recruiting NCT05086705
31 Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice) Recruiting NCT04496739
32 Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women With Breast Cancer - HeNRIetta Recruiting NCT02515110
33 LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients Recruiting NCT05410951
34 Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON) Active, not recruiting NCT01706432
35 Understanding How CDH1 Germline Mutations Affect Hereditary Lobular Breast Cancer Active, not recruiting NCT04206891
36 Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Active, not recruiting NCT04021069
37 Soy Treatment for High-risk Women Active, not recruiting NCT01219075
38 Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute Not yet recruiting NCT05178498
39 Intraoperative Stereotactic Image-guided Navigation of Perforators for DIEP Flap Breast Reconstruction. Withdrawn NCT01729832

Search NIH Clinical Center for Breast Lobular Carcinoma

Genetic Tests for Breast Lobular Carcinoma

Genetic tests related to Breast Lobular Carcinoma:

# Genetic test Affiliating Genes
1 Breast Lobular Carcinoma 28

Anatomical Context for Breast Lobular Carcinoma

Organs/tissues related to Breast Lobular Carcinoma:

MalaCards : Breast, Lymph Node, Bone Marrow, Colon, Skeletal Muscle, Bone, Thyroid

Publications for Breast Lobular Carcinoma

Articles related to Breast Lobular Carcinoma:

(show top 50) (show all 405)
# Title Authors PMID Year
1
Germline E-cadherin mutations in familial lobular breast cancer. 5
17660459 2007
2
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. 5
8557030 1995
3
De novo metastatic lobular breast carcinoma: A population-based study from SEER database. 62
35012851 2022
4
Genomic assays for lobular breast carcinoma. 62
36451999 2022
5
Plexiform tumorlet in a woman with postmenopausal endometrioid endometrial carcinoma taking tamoxifen for breast cancer: A case report. 62
36389630 2022
6
Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. 62
35665642 2022
7
Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas. 62
35906698 2022
8
Efficacy of breast magnetic resonance for surgical decision in mixed invasive ductal and lobular breast carcinoma. 62
35382971 2022
9
Metastatic Neoplasms Involving the Stomach. 62
34875001 2022
10
Development of Histologically Verified Thyroid Diseases in Women Operated for Breast Cancer: A Review of the Literature and a Case Series. 62
35683541 2022
11
Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer. 62
35437308 2022
12
Metastatic Breast Cancer Presenting as Progressive Ophthalmoplegia 30 Years After Initial Cancer Diagnosis. 62
34417769 2022
13
Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. 62
34889530 2022
14
Palpable multifocal and multicentric invasive lobular breast carcinoma in a young female. 62
34876947 2022
15
Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ. 62
34920159 2022
16
Case Report: Male Lobular Breast Cancer in Hereditary Cancer Syndromes. 62
35686104 2022
17
Uterine metastasis of lobular breast carcinoma under tamoxifen therapy: A case report. 62
34777802 2021
18
Infiltrative pattern of metastatic invasive lobular breast carcinoma in the abdomen: a pictorial review. 62
34894297 2021
19
Histiocytoid variant of invasive lobular breast carcinoma. A case report and literature review. 62
34868577 2021
20
Gastric metastasis before diagnosis of primary invasive lobular breast carcinoma: a rare case presentation from Pakistan. 62
34569446 2021
21
Duodenal and Biliary Obstruction due to Extrinsic CompressionDuodenal and Biliary Obstruction due to Extrinsic Compression by Recurrent Lobular Breast Carcinoma: A Case Report. 62
34720837 2021
22
Occult Disseminated Metastatic Breast Carcinoma Presenting as Acquired Thrombotic Thrombocytopenic Purpura. 62
35111014 2021
23
p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma. 62
33237989 2021
24
Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. 62
33753865 2021
25
Synchronous metastases of infiltrating lobular breast carcinoma to stomach and colon: ; rare but it does occur. 62
34565039 2021
26
Lobular to Lobule: Metastatic Breast Carcinoma to Olfactory Neuroblastoma. 62
32661671 2021
27
An individualized food-based nutrition intervention reduces visceral and total body fat while preserving skeletal muscle mass in breast cancer patients under antineoplastic treatment. 62
33485708 2021
28
Breast carcinoma metastasising to the gastric wall and the peritoneum: what physicians need to know. 62
33980555 2021
29
Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. 62
34001921 2021
30
Metastatic lobular carcinoma of the breast found incidentally on pathology following cholecystectomy for chronic cholecystitis: A case report. 62
33636408 2021
31
Oncological cases and complications in Urology. 62
33754614 2021
32
[From an enterovesical fistula to mammary carcinoma]. 62
33757143 2021
33
Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population. 62
33544698 2021
34
Colorectal and gastric metastases from lobular breast cancer that resembled superficial neoplastic lesions. 62
33159678 2021
35
Signet-ring cell/histiocytoid carcinoma in the axilla: A case report with genetic analysis using next-generation sequencing. 62
32770562 2021
36
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. 62
33468209 2021
37
Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. 62
33148662 2021
38
The Impact of Radiotherapy on the Incidence of Secondary Malignancies: A Pan-Cancer Study in the US SEER Cancer Registries. 62
33435562 2021
39
An unusual presentation of cutaneous metastatic lobular breast carcinoma. 62
33651872 2021
40
Unexpected diagnosis of metastatic breast carcinoma in an endomyocardial biopsy done for cardiac allograft rejection evaluation. 62
32814149 2021
41
A Rare Metastatic Site of Invasive Lobular Breast Carcinoma: A Case Report. 62
34853710 2021
42
Enophthalmos as the Initial Systemic Finding of Undiagnosed Metastatic Breast Carcinoma. 62
33536796 2021
43
Metastases to the Stomach: Clinicopathologic Features of Metastases Mimicking Gastric Primaries. 62
34514560 2021
44
Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/β-Catenin Complex and Associated Genetic Alterations. 62
34804623 2021
45
Triple negative lobular breast carcinoma metastatic to an ovarian fibrothecoma. 62
32508260 2020
46
Asymptomatic solitary metastasis to the stomach from breast cancer: A case report. 62
33005409 2020
47
Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status. 62
33058542 2020
48
Interaction Between Cyclosporine and Palbociclib in a Renal Transplant Patient: Case Report and Pharmacokinetic Perspective. 62
31248333 2020
49
Colon metastases as first clinical manifestation of lobular breast carcinoma with no subsequent evidence of breast disease. 62
33257365 2020
50
Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. 62
32404955 2020

Variations for Breast Lobular Carcinoma

ClinVar genetic disease variations for Breast Lobular Carcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CDH1 NM_004360.5(CDH1):c.781G>T (p.Glu261Ter) SNV Pathogenic
12234 rs121964873 GRCh37: 16:68844193-68844193
GRCh38: 16:68810290-68810290
2 CDH1 NM_004360.5(CDH1):c.521dup (p.Asn174fs) DUP Pathogenic
140803 rs587781290 GRCh37: 16:68842455-68842456
GRCh38: 16:68808552-68808553
3 CDH1 NM_004360.5(CDH1):c.1493A>C (p.Asp498Ala) SNV Not Provided
234528 rs876661065 GRCh37: 16:68849590-68849590
GRCh38: 16:68815687-68815687

Cosmic variations for Breast Lobular Carcinoma:

8 (show top 50) (show all 3466)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88264551 ZRSR2 breast,NS,carcinoma,lobular carcinoma c.772-1G>C p.? 23:15818586-15818586 8
2 COSM87279654 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.4556C>G p.S1519* 16:72798126-72798126 8
3 COSM149285883 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.4556C>G p.S1519* 16:72798126-72798126 8
4 COSM149315898 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.7262C>G p.S2421* 16:72795420-72795420 8
5 COSM102029000 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.1814C>G p.S605* 16:72798126-72798126 8
6 COSM102040958 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.4520C>G p.S1507* 16:72795420-72795420 8
7 COSM102023834 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.6478C>T p.Q2160* 16:72793462-72793462 8
8 COSM149270832 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.9220C>T p.Q3074* 16:72793462-72793462 8
9 COSM87290679 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.7262C>G p.S2421* 16:72795420-72795420 8
10 COSM87274898 ZFHX3 breast,NS,carcinoma,lobular carcinoma c.9220C>T p.Q3074* 16:72793462-72793462 8
11 COSM136835751 YES1 breast,NS,carcinoma,lobular carcinoma c.1105G>C p.D369H 18:739782-739782 8
12 COSM152021957 YES1 breast,NS,carcinoma,lobular carcinoma c.1090G>C p.D364H 18:739782-739782 8
13 COSM89893843 YES1 breast,NS,carcinoma,lobular carcinoma c.1090G>C p.D364H 18:739782-739782 8
14 COSM133268543 YAP1 breast,NS,carcinoma,lobular carcinoma c.1078C>T p.Q360* 11:102223703-102223703 8
15 COSM145023934 YAP1 breast,NS,carcinoma,lobular carcinoma c.964C>T p.Q322* 11:102223703-102223703 8
16 COSM128447630 YAP1 breast,NS,carcinoma,lobular carcinoma c.952C>T p.Q318* 11:102223703-102223703 8
17 COSM127994003 YAP1 breast,NS,carcinoma,lobular carcinoma c.1066C>T p.Q356* 11:102223703-102223703 8
18 COSM126968980 YAP1 breast,NS,carcinoma,lobular carcinoma c.580C>T p.Q194* 11:102223703-102223703 8
19 COSM85232645 YAP1 breast,NS,carcinoma,lobular carcinoma c.1114C>T p.Q372* 11:102223703-102223703 8
20 COSM143037036 YAP1 breast,NS,carcinoma,lobular carcinoma c.1126C>T p.Q376* 11:102223703-102223703 8
21 COSM90943480 YAP1 breast,NS,carcinoma,lobular carcinoma c.1012C>T p.Q338* 11:102223703-102223703 8
22 COSM101979646 XPO1 breast,NS,carcinoma,lobular carcinoma c.1160C>G p.S387C 2:61493979-61493979 8
23 COSM104239359 XPO1 breast,NS,carcinoma,lobular carcinoma c.1160C>G p.S387C 2:61493979-61493979 8
24 COSM104241154 XPO1 breast,NS,carcinoma,lobular carcinoma c.2260G>T p.E754* 2:61488218-61488218 8
25 COSM104886058 XPO1 breast,NS,carcinoma,lobular carcinoma c.1160C>G p.S387C 2:61493979-61493979 8
26 COSM101981526 XPO1 breast,NS,carcinoma,lobular carcinoma c.2260G>T p.E754* 2:61488218-61488218 8
27 COSM104888500 XPO1 breast,NS,carcinoma,lobular carcinoma c.2260G>T p.E754* 2:61488218-61488218 8
28 COSM108081568 XIAP breast,NS,carcinoma,lobular carcinoma c.1240C>G p.L414V 23:123900633-123900633 8
29 COSM92178574 XIAP breast,NS,carcinoma,lobular carcinoma c.1240C>G p.L414V 23:123900633-123900633 8
30 COSM94288275 XIAP breast,NS,carcinoma,lobular carcinoma c.1240C>G p.L414V 23:123900633-123900633 8
31 COSM90876009 WNK1 breast,NS,carcinoma,lobular carcinoma c.6569C>G p.S2190C 12:900596-900596 8
32 COSM130224650 WNK1 breast,NS,carcinoma,lobular carcinoma c.7349C>G p.S2450C 12:900596-900596 8
33 COSM128151609 WNK1 breast,NS,carcinoma,lobular carcinoma c.7808C>G p.S2603C 12:900596-900596 8
34 COSM132334333 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 8
35 COSM132334343 WNK1 breast,NS,carcinoma,lobular carcinoma c.5825C>G p.S1942C 12:900596-900596 8
36 COSM90876002 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 8
37 COSM130224638 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 8
38 COSM92011980 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 8
39 COSM128151601 WNK1 breast,NS,carcinoma,lobular carcinoma c.1255G>C p.E419Q 12:830104-830104 8
40 COSM92011987 WNK1 breast,NS,carcinoma,lobular carcinoma c.7325C>G p.S2442C 12:900596-900596 8
41 COSM88292485 VHL breast,NS,carcinoma,lobular carcinoma c.241C>T p.P81S 3:10142088-10142088 8
42 COSM90665450 VHL breast,NS,carcinoma,lobular carcinoma c.439C>G p.L147V 3:10149885-10149885 8
43 COSM90653017 VHL breast,NS,carcinoma,lobular carcinoma c.241C>T p.P81S 3:10142088-10142088 8
44 COSM88303015 VHL breast,NS,carcinoma,lobular carcinoma c.562C>G p.L188V 3:10149885-10149885 8
45 COSM133858401 USP28 breast,NS,carcinoma,lobular carcinoma c.1675G>A p.D559N 11:113809177-113809177 8
46 COSM83992324 USP28 breast,NS,carcinoma,lobular carcinoma c.2050G>A p.D684N 11:113809177-113809177 8
47 COSM132241970 USP28 breast,NS,carcinoma,lobular carcinoma c.1174G>A p.D392N 11:113809177-113809177 8
48 COSM140659623 TTN breast,NS,carcinoma,lobular carcinoma c.97193-1G>C p.? 2:178542564-178542564 8
49 COSM96773374 TTN breast,NS,carcinoma,lobular carcinoma c.10945G>A p.E3649K 2:178741574-178741574 8
50 COSM139462905 TTN breast,NS,carcinoma,lobular carcinoma c.40301G>A p.R13434K 2:178621600-178621600 8

Expression for Breast Lobular Carcinoma

Search GEO for disease gene expression data for Breast Lobular Carcinoma.

Pathways for Breast Lobular Carcinoma

Pathways related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 TP53 PTEN PIP MUC1 ESR1 ERBB2
2
Show member pathways
13.78 BRCA1 BRCA2 CDH1 CTNND1 CYP19A1 EGF
3 13.74 AR CDH1 CTNND1 EGF EGFR ERBB2
4
Show member pathways
13.5 BRCA1 BRCA2 EGF EGFR ERBB2 PIK3CA
5
Show member pathways
13.43 TP53 PTEN PIP ERBB2 EGFR EGF
6
Show member pathways
13.33 CDH1 CTNND1 EGF EGFR ERBB2 PIP
7
Show member pathways
13.09 TP53 PTEN PIK3CA ESR1 ERBB2 EGFR
8
Show member pathways
13.01 PIK3CA PGR GATA3 FOXA1 ESR1 EGFR
9
Show member pathways
12.97 TP53 PTEN PIK3CA FOXA1 EGFR EGF
10 12.87 CTNND1 EGF EGFR ERBB2 ESR1 PGR
11
Show member pathways
12.85 TP53 PTEN GATA3 ESR1 BRCA1 AR
12
Show member pathways
12.72 EGF EGFR ERBB2 ESR1 PIK3CA PTEN
13 12.71 TP53 PTEN PIK3CA EGFR EGF CDH1
14
Show member pathways
12.59 TP53 PTEN PIK3CA ERBB2 EGFR EGF
15 12.57 MUC1 KRT7 KRT5 CTNND1 CDH1
16
Show member pathways
12.5 TP53 PTEN PIK3CA ESR1 ERBB2 CDH1
17
Show member pathways
12.46 TP53 PIK3CA ERBB2 EGFR
18
Show member pathways
12.43 PIK3CA ESR1 EGFR EGF
19
Show member pathways
12.41 CDH1 EGF EGFR ERBB2 PIK3CA
20
Show member pathways
12.36 PIK3CA ESR1 ERBB2 EGFR EGF
21
Show member pathways
12.35 TP53 PIK3CA MUC1 ERBB2 EGFR EGF
22 12.32 PTEN PIK3CA ERBB2 EGFR EGF
23
Show member pathways
12.3 PTEN PIK3CA EGFR EGF
24
Show member pathways
12.29 TP53 PTEN PIK3CA GATA3
25
Show member pathways
12.27 PIK3CA ERBB2 EGFR EGF
26
Show member pathways
12.25 TP53 PTEN PIK3CA ERBB2 EGFR
27 12.22 TP53 EGFR EGF CDH1
28 12.13 TP53 PTEN ERBB2 EGFR
29
Show member pathways
12.1 PTEN PIK3CA ERBB2 EGFR EGF AR
30 12.09 TP53 PTEN FOXA1 EGFR
31
Show member pathways
12.09 TP53 PTEN PIK3CA PGR ESR1 ERBB2
32
Show member pathways
12.07 EGF EGFR ERBB2 PIK3CA
33
Show member pathways
12.06 TP53 PIK3CA ERBB2 EGFR
34
Show member pathways
12.03 PIK3CA PGR ESR1 ERBB2 EGFR EGF
35
Show member pathways
12.01 EGF EGFR ERBB2 PIK3CA PTEN
36 11.96 TP53 PTEN PIK3CA ERBB2
37
Show member pathways
11.87 ESR1 ERBB2 EGFR
38
Show member pathways
11.84 BRCA1 BRCA2 TP53
39 11.82 TP53 BRCA2 BRCA1
40 11.8 TP53 KRT5 GATA3
41 11.79 TP53 PTEN PIK3CA ERBB2 EGFR
42 11.78 GATA3 ESR1 AR
43 11.78 TP53 PTEN ESR1
44 11.74 TP53 PTEN ESR1
45 11.73 ESR1 EGFR EGF
46 11.71 PGR ESR1 BRCA1
47 11.67 TP53 PTEN PIK3CA ERBB2 BRCA1
48
Show member pathways
11.66 TP53 PTEN PIK3CA
49
Show member pathways
11.66 PIK3CA ERBB2 EGFR EGF
50 11.62 PIK3CA EGFR EGF

GO Terms for Breast Lobular Carcinoma

Cellular components related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear ubiquitin ligase complex GO:0000152 8.92 BRCA2 BRCA1

Biological processes related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.32 TP53 GATA3 ESR1 EGFR EGF CDH1
2 positive regulation of protein kinase B signaling GO:0051897 10.18 PIK3CA GATA3 EGFR EGF
3 cellular response to ionizing radiation GO:0071479 10.06 TP53 BRCA2 BRCA1
4 negative regulation of epithelial to mesenchymal transition GO:0010719 10.04 PTEN GATA3 FOXA1
5 phosphatidylinositol 3-kinase signaling GO:0014065 10.03 PTEN PIK3CA GATA3 ERBB2
6 positive regulation of phosphorylation GO:0042327 10.01 EGFR EGF AR
7 response to gamma radiation GO:0010332 9.99 TP53 GATA3 BRCA2
8 uterus development GO:0060065 9.97 GATA3 ESR1 CYP19A1
9 mammary gland alveolus development GO:0060749 9.95 ESR1 EGF AR
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.93 BRCA2 MUC1 TP53
11 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.91 TP53 MUC1
12 cellular response to indole-3-methanol GO:0071681 9.9 CDH1 BRCA1
13 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.89 TP53 ESR1
14 intracellular steroid hormone receptor signaling pathway GO:0030518 9.88 PGR ESR1 AR
15 cell population proliferation GO:0008283 9.87 BRCA2 EGF EGFR GATA3 PTEN TP53
16 negative regulation of mammary gland epithelial cell proliferation GO:0033600 9.86 BRCA2 GATA3
17 morphogenesis of an epithelial fold GO:0060571 9.85 AR EGFR
18 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.83 PGR AR
19 positive regulation of gene expression GO:0010628 9.8 TP53 PIP PGR GATA3 ERBB2 EGF
20 chordate embryonic development GO:0043009 9.78 BRCA2 BRCA1
21 prostate gland growth GO:0060736 9.73 PTEN CYP19A1 AR
22 ERBB2-EGFR signaling pathway GO:0038134 9.63 ERBB2 EGFR EGF
23 positive regulation of miRNA transcription GO:1902895 9.17 TP53 GATA3 FOXA1 EGFR AR

Molecular functions related to Breast Lobular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 10.21 TP53 PGR GATA3 FOXA1 ESR1 AR
2 identical protein binding GO:0042802 10.2 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
3 transcription cis-regulatory region binding GO:0000976 10.1 TP53 GATA3 FOXA1 BRCA1 AR
4 beta-catenin binding GO:0008013 9.92 ESR1 CTNND1 CDH1 AR
5 ATPase binding GO:0051117 9.86 PGR ESR1 EGFR AR
6 steroid binding GO:0005496 9.85 AR ESR1 PGR
7 enzyme binding GO:0019899 9.8 TP53 PTEN PGR ESR1 EGFR BRCA1
8 transcription coactivator binding GO:0001223 9.23 PGR GATA3 ESR1 AR

Sources for Breast Lobular Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....